Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab
NCT02309281
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG:
aflibercept 2mg
Sponsor
Vista Klinik
Collaborators
[object Object]